Clinical Trials Logo

Intestinal Diseases clinical trials

View clinical trials related to Intestinal Diseases.

Filter by:

NCT ID: NCT03843697 Not yet recruiting - Clinical trials for Inflammatory Bowel Diseases

A Trial for Prevention of Loss of the Effect of Biological Drugs in Patients With Inflammatory Bowel Disease

Start date: March 1, 2019
Phase: N/A
Study type: Interventional

Trial for IBD patients non-responsive to biological drugs, using medical app reminding patients to take their physician-prescribed medications

NCT ID: NCT03841942 Not yet recruiting - Clinical trials for Inflammatory Bowel Diseases

Spacing of Infliximab Therapy

SPACIFIX
Start date: April 1, 2019
Phase: N/A
Study type: Interventional

Comparison of trough level-based spacing and clinical-based spacing of infliximab infusions in patients with inflammatory bowel disease in deep remission A prospective, multicenter, open-label, randomized, controlled Study

NCT ID: NCT03841513 Recruiting - Clinical trials for Pelvic Organ Prolapse

Minimally Invasive Burch Colposuspension to Reduce Occult Stress Incontinence

MICRO
Start date: January 29, 2019
Phase: N/A
Study type: Interventional

This study evaluates the addition of a laparoscopic Burch colposuspension procedure at the time of laparoscopic sacrocolpopexy to prevent stress urinary incontinence. Half of the participants will undergo Burch colposuspension procedure at the time of sacrocolpopexy, and half of the participants will undergo sacrocolpopexy alone.

NCT ID: NCT03841045 Recruiting - Crohn Disease Clinical Trials

Unraveling a Potential Connection Between Bilirubin Metabolism, Gut Microbiota and Inflammatory Bowel Diseases

Start date: September 14, 2016
Phase:
Study type: Observational

Inflammatory Bowel Diseases (IBDs) are a set of recurrent inflammatory conditions that include the colon and small intestine. The two principal conditions include Crohn's disease (CD) and ulcerative colitis (UC). The etiology of which is likely to stem from the interplay of gut microbial imbalances and host. In this study stool cultures, saliva and skin samples will be taken from all participants.

NCT ID: NCT03840707 Not yet recruiting - Clinical trials for Inflammatory Bowel Diseases

LIFEwithIBD: Living With Intention, Fullness and Engagement With Inflammatory Bowel Disease

LIFEwithIBD
Start date: April 1, 2019
Phase: N/A
Study type: Interventional

This investigation aims to apply and test the feasibility of an acceptance, mindfulness and compassionate-based intervention structured for inflammatory bowel disease patients. LIFEwithIBD programme for inflammatory bowel disease thus comprises 9 weekly group sessions, lasting 1 and a half hour each, run in small groups at a Gastroenterology Service at the Coimbra's University Hospital. For each week participants have assigned homework (e.g., mindfulness exercises). The efficacy of LIFE-IBD Group Intervention to improve quality of life, mental health, and disease activity-related scores will be tested in a sample of Portuguese patients. Additionally, this study expected that the observable changes after the intervention completion will be attributed to changes in emotional regulation processes and maintained over the follow-up periods.

NCT ID: NCT03836612 Not yet recruiting - Ulcerative Colitis Clinical Trials

Healthcare Resource Utilisation, Common Mental Health Problems, and Infections in People With Inflammatory Bowel Disease

Start date: February 1, 2019
Phase:
Study type: Observational

Ulcerative colitis and Crohn's disease are the commonest types of inflammatory bowel disease (IBD). Both conditions range in severity from no symptoms to being potentially fatal. Both conditions are treated with medications which suppress the immune system. It is not known whether this increases the risk for infections and cancers in these conditions. It is also recognised by healthcare professionals that these conditions cause a considerable amount of psychological distress. However, this has never been measured in a large population sample. This study will investigate any associations with treatment and new onset infections and cancer. They will also examine the relationship between IBD and common mental health problems (specifically, depression and anxiety) and the impact that these have on the healthcare use (including number of general practitioner [GP] appointments, hospital attendances, and medication prescriptions. Combined, these studies should provide a better understanding of the impact of IBD on affected people and provide evidence to support the correct allocation of healthcare resources.

NCT ID: NCT03833999 Recruiting - Ondansetron Clinical Trials

Mode of Action of Ondansetron, a 5-HT Receptor 3 Antagonist, in Lactulose Induced Diarrhoea

MOLID
Start date: October 16, 2018
Phase: Phase 4
Study type: Interventional

This is a double-blind, two period, two treatment crossover trial of ondansetron verses placebo studying the effects of ondansetron in the small and large bowel, specifically its effects on the amount of water in the gut, measured by MRI.

NCT ID: NCT03833778 Recruiting - Clinical trials for Chronic Inflammatory Intestinal Diseases (CED)

Kids + Adolescents Research Learning On Tablet Teaching Aachen

KARLOTTA
Start date: February 5, 2019
Phase: N/A
Study type: Interventional

The aim of this study plan is to implement a tablet quiz in the German-speaking area, in order to test the specific knowledge about chronic inflammatory intestinal diseases (CED) concerning pediatric patients in the context of an age-appropriated and interesting digital playing environment, and to process knowledge gaps at the subsequent doctor's contact. The quiz should be combined with a game and can be performed by the patients, while they wait in the ambulance for their doctor's appointment. The investigator's goals are to grasp playfully gaps in the CED knowledge regarding the patients and to use these in the following consulting hour for clarification and advice in line with a better understanding of the disease. With this, the specific knowledge, the understanding of the disease, the therapeutic adherence, and the self-efficacy should improve the self-responsible handling of the disease. In particular, the willingness of the group of older teenagers to transit into the adult medicine can be collected and processed. The investigators want to check the efficacy in a randomized, controlled study with two groups of 15 pediatric CED patients. The hypothesis is that the additional play of the tablet-CED-quiz and the individualized advice have a positive impact on the CED knowledge, the disease activity, the CED-related life quality and the willingness of teenagers for transition.

NCT ID: NCT03833310 Not yet recruiting - Clinical trials for Inflammatory Bowel Diseases

Osteoprotegerin and sRANKL as Marker in Early Diagnosis of Inflammatory Bowel Disease

Start date: June 20, 2019
Phase:
Study type: Observational

The inflammatory bowel diseases represent a heterogeneous group of chronic , relapsing- inflammatory disorders of the gastrointestinal tract. Crohn's disease and ulcerative colitis are the two major clinical forms.The global incidence and prevalence of the inflammatory bowel diseases has increased over the last 2-4 decades . Despite the great progress in understanding the pathogenesis of these diseases, their etiology remains unclear . Considerable effort has been devoted to the development of an accurate ,noninvasive biomarkers that have increased diagnostic sensitivity and specificity . Osteoprotegerin is a member of the Tumor Necrosis Factor Receptor superfamily of proteins. Osteoprotegerin is of particular importance in bone metabolism, inflammation , tumorigenesis, and other processes where cell differentiation, survival, and death are controlled. Osteoprotegerin activates inflammation in the gut by stimulating immune cells, cytokines, and the Necrosis factor-κappaB pathway . Soluble Receptor activator of nuclear factor kappa-Β ligand is known as a type II membrane protein and as a member of tumor necrosis factor superfamily . Soluble Receptor activator of nuclear factor kappa-Β ligand has been identified to affect the immune system and a binding partner of ( Osteoprotegerin ), and controls cell proliferation.The interactions between Osteoprotegerin and Soluble Receptor activator of nuclear factor kappa-Β ligand, Soluble Receptor activator of nuclear factor kappa-Β have relevance to inflammatory pathways. Soluble Receptor activator of nuclear factor kappa-Β ligand- Soluble Receptor activator of nuclear factor kappa-Β ligand binding activates pathways that contribute to the survival of T-lymphocytes and dendritic cells . Calprotectin is a group of protein heterocomplexes that are expressed mainly in neutrophil and monocyte cytosols . It has been shown that calprotectin concentration markedly increases in bowel disorders, such as Crohn's disease , UlcerativeCoilits, and colonic neoplasia.

NCT ID: NCT03831750 Enrolling by invitation - Clinical trials for Inflammatory Bowel Diseases

Assessing the Effectiveness of a Stress Reduction Intervention in Inflammatory Bowel Disease (IBD)

Start date: March 2019
Phase: N/A
Study type: Interventional

The investigators have designed a guided, online, tri-component, stress reduction intervention for participants with inflammatory bowel diseases. In two blinded randomized controlled trials (categorized by disease subtype: UC and CD), the investigators will assess the impact of an online 3-month stress reduction intervention on perceived stress level (primary outcome) and the following (secondary outcomes): anxiety, depression, IBD disease activity (e.g., changes in CRP, fecal calprotectin, medication, hospitalization, or surgery), serum inflammatory markers, serum and salivary markers of stress, stress-resilience, and health- related quality of life. Participant satisfaction and adherence to the intervention will be evaluated.relative to the control group plus standard care.